000 | 01989 a2200529 4500 | ||
---|---|---|---|
005 | 20250516083348.0 | ||
264 | 0 | _c20121108 | |
008 | 201211s 0 0 eng d | ||
022 | _a1523-4681 | ||
024 | 7 |
_a10.1002/jbmr.1606 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMcCloskey, Eugene V | |
245 | 0 | 0 |
_aDenosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. _h[electronic resource] |
260 |
_bJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research _cJul 2012 |
||
300 |
_a1480-6 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 | _aAlgorithms |
650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
650 | 0 | 4 | _aBody Mass Index |
650 | 0 | 4 |
_aBone Density Conservation Agents _xtherapeutic use |
650 | 0 | 4 | _aDenosumab |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFracture Healing |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aOsteoporosis _xdrug therapy |
650 | 0 | 4 |
_aOsteoporotic Fractures _xprevention & control |
650 | 0 | 4 | _aPlacebos |
650 | 0 | 4 | _aPostmenopause |
650 | 0 | 4 | _aProbability |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 | _aRisk |
650 | 0 | 4 | _aRisk Assessment |
700 | 1 | _aJohansson, Helena | |
700 | 1 | _aOden, Anders | |
700 | 1 | _aAustin, Matt | |
700 | 1 | _aSiris, Ethel | |
700 | 1 | _aWang, Andrea | |
700 | 1 | _aLewiecki, E Michael | |
700 | 1 | _aLorenc, Roman | |
700 | 1 | _aLibanati, Cesar | |
700 | 1 | _aKanis, John A | |
773 | 0 |
_tJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research _gvol. 27 _gno. 7 _gp. 1480-6 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1002/jbmr.1606 _zAvailable from publisher's website |
999 |
_c21635687 _d21635687 |